DYN vs PVLA
DYN: Dyne Therapeutics is a clinical-stage biotechnology company developing targeted muscle therapeutics for rare diseases using its proprietary FORCE platform. PVLA: A clinical-stage biopharmaceutical company developing proprietary therapeutics for rare skin diseases and vascular malformations following the merger of Pieris Pharmaceuticals and Legacy Palvella.
Side-by-side fundamentals
| Metric | DYN | PVLA | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $25.18 | $141.77 | |
| Market cap as of 2026-08-03 | $4.7B | $2.0B | |
| Net margin as of 2026-08-03 | n/a | -39.7% | |
| Operating margin as of 2026-08-03 | n/a | -47.8% | |
| ROE as of 2026-08-03 | -58.3% | -56.9% | PVLA higher |
| ROA as of 2026-08-03 | -46.8% | -42.5% | PVLA higher |
| Debt / equity as of 2026-08-03 | 0.18 | 0.09 | PVLA lower |
| Revenue growth (YoY) as of 2026-08-03 | n/a | -97.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +13.4% | |
| Beta as of 2026-08-03 | 1.79 | -0.20 | |
| 1-year return as of 2026-07-31 close | +155.6% | +267.1% | PVLA higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.